John Rakow's most recent trade in Adverum Biotechnologies Inc was a trade of 75,257 Performance Based Stock Option (Right to Buy) done . Disclosure was reported to the exchange on Sept. 14, 2022.
Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
---|---|---|---|---|---|---|---|---|---|---|
Adverum Biotechnologies Inc | John Rakow | SVP, Genl Counsel, Acting CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Sep 2022 | 75,257 | 75,257 | - | - | Performance Based Stock Option (Right to Buy) | |
Adverum Biotechnologies Inc | John Rakow | SVP, Genl Counsel, Acting CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Sep 2022 | 42,813 | 42,813 | - | - | Stock Option (Right to Buy) | |
Adverum Biotechnologies Inc | John Rakow | SVP, Genl Counsel, Acting CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2022 | 250,000 | 250,000 | - | - | Stock Option (Right to Buy) |